Gościniak Anna, Kocaj Filip, Stasiłowicz-Krzemień Anna, Szymański Marcin, Karpiński Tomasz M, Cielecka-Piontek Judyta
Department of Pharmacognosy and Biomaterials, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland.
Center for Advanced Technologies, Adam Mickiewicz University in Poznań, Uniwersytetu Poznańskiego 10, 61-614 Poznan, Poland.
Gels. 2024 Nov 26;10(12):770. doi: 10.3390/gels10120770.
The therapeutic potential of L. extract has gained significant attention due to its diverse medical applications. Sublingual administration remains a common delivery method of cannabinoids; however, challenges often arise due to the inconvenient form of the extract and its taste. To address these issues, a novel bigel formulation was developed, combining water and oil phases to enhance stability and bioavailability. This formulation incorporates a cannabidiol-rich hemp extract, hyaluronic acid for its moisturizing properties, and a taste-masking agent to improve patient compliance and comfort. Using a standardized hemp extract rich in cannabinoids and a well-characterized terpene profile, the printability of the bigels was evaluated through 3D printing technology. A printout with known cannabidiol (CBD) and cannabidiolic acid (CBDA) content of 11.613 mg ± 0.192 of CBD and 4.732 mg ± 0.280 of CBDA in the printout was obtained. In addition, the release profile of CBD and CBDA was evaluated to determine the delivery efficiency of the active ingredient-dissolved active ingredient levels ranged from 74.84% ± 0.50 to 80.87% ± 3.20 for CBD and from 80.84 ± 1.33 to 98.31 ± 1.70 for CBDA depending on the formulation. Rheological studies were conducted to evaluate the viscosity of the bigels under varying temperature conditions, ensuring their stability and usability. Findings suggest that this 3D-printed bigel formulation could significantly enhance the delivery of cannabis extracts, offering a more convenient and effective therapeutic option for patients. This research underscores the importance of innovation in cannabinoid therapies and paves the way for further advancements in personalized medicine.
L.提取物的治疗潜力因其多样的医学应用而备受关注。舌下给药仍是大麻素常见的给药方式；然而，由于提取物不便的剂型及其味道，常常会出现问题。为解决这些问题，开发了一种新型双凝胶制剂，将水相和油相结合以提高稳定性和生物利用度。该制剂包含富含大麻二酚的大麻提取物、具有保湿特性的透明质酸以及掩味剂，以提高患者的顺应性和舒适度。使用富含大麻素且萜类成分特征明确的标准化大麻提取物，通过3D打印技术评估了双凝胶的可打印性。打印出的制剂中，已知大麻二酚（CBD）和大麻二酚酸（CBDA）的含量分别为11.613 mg±0.192（CBD）和4.732 mg±0.280（CBDA）。此外，还评估了CBD和CBDA的释放曲线，以确定活性成分的递送效率——根据制剂不同，溶解的活性成分水平，CBD为74.84%±0.50至80.87%±3.20，CBDA为80.84±1.33至98.31±1.70。进行了流变学研究，以评估双凝胶在不同温度条件下的粘度，确保其稳定性和可用性。研究结果表明，这种3D打印的双凝胶制剂可显著提高大麻提取物的递送效果，为患者提供更方便有效的治疗选择。这项研究强调了大麻素疗法创新的重要性，并为个性化医学的进一步发展铺平了道路。
